Ventricular Septal DefectCAUTION 2NCT06676345
Mechanical Complications of Acute Myocardial Infarction: a Multicenter Prospective Study
An observational study of Ventricular Septal Defect and Papillary Muscle Rupture, run by Maastricht University Medical Center at 1 site in Italy.
Trial summary
In 2019, the international study titled "CAUTION Study - 1" (MeChanical complicAtions of acUte myocardial infarcTion: an InternatiOnal multiceNter cohort study), a retrospective multicenter study, was launched and registered on ClinicalTrials.gov (Identifier: NCT03848429). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ventricular Septal Defect, Papillary Muscle Rupture, Cardiac Rupture
- What is being tested?
- Surgical treatment and Percutaneous treatment
- Type of treatment
- Surgery or procedure
- How many people
- 800 participants
- Where
- 1 siteItaly
- Study dates
- 1 Jan 2025to 31 Dec 2032
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients diagnosed with post-infarction mechanical complications
Who may be able to join
- all the patients diagnosed with post-infarction mechanical complications, independently from the treatment assigned
Who cannot join
- patients with cardiac rupture not acute myocardial infarction related
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
ASST dei Sette Laghi
Varese
Matteo Matteucci, MD
About this study
Official title: Mechanical Complications of Acute Myocardial Infarction: a Multicenter Prospective Observational Study
In 2019, the international study titled "CAUTION Study - 1" (MeChanical complicAtions of acUte myocardial infarcTion: an InternatiOnal multiceNter cohort study), a retrospective multicenter study, was launched and registered on ClinicalTrials.gov (Identifier: NCT03848429). This study highlighted the outcomes of surgical treatment of post-infarction mechanical complications in patients operated between 2000 and 2019. Several scientific publications have resulted from this registry, which involved 27 international centers and recruited about 800 patients. However, retrospective studies are inherently limited by factors such as selection bias and a high number of missing data, affecting data interpretation and consistency of results. Moreover, most registries report only data about surgical patients or, in rare situations, about patients treated percutaneously. To overcome these limitations, a prospective study has been designed to collect more precise and focused data and achieve results that better reflect the current clinical practice, including all the patients diagnosed with post-infarction mechanical complications, independently from the treatment assigned.
"CAUTION Study - 2" is, therefore, a prospective, multicenter cohort study with the primary aim of analyzing the outcomes of surgical, percutaneous and conservative treatment of post-infarction mechanical complications in the contemporary era.
Read the detailed description
In Western countries, cardiovascular diseases are the leading cause of death among people over 65 years old. Acute myocardial infarction represents the most frequent cardiovascular event among the heart diseases. In recent years, with the spread of percutaneous coronary reperfusion techniques, there has been a reduction in the incidence of mechanical complications of acute myocardial infarction. However, mortality in patients who develop one of these complications remains high, with mechanical complications representing a relevant cause of death in patients with acute coronary syndrome after cardiogenic shock and arrhythmia.
The acute mechanical complications of myocardial infarction include ventricular free-wall rupture (VFWR), ventricular pseudo-aneurysm, acute mitral regurgitation due to papillary muscle rupture (PMR), and ventricular septal rupture (VSR). Numerous surgical techniques and management protocols have been proposed to address these complications, but the most effective ones and those associated with better outcomes remain unclear. Recently, percutaneous treatment techniques have also been proposed in this setting (particularly for VSD and PMR), especially for high-risk surgical patients or those considered inoperable, though the safety and efficacy of these approaches remain uncertain.
In 2019, the international study titled "CAUTION Study - 1" (MeChanical complicAtions of acUte myocardial infarcTion: an InternatiOnal multiceNter cohort study), a retrospective multicenter study, was launched and registered on ClinicalTrials.gov (Identifier: NCT03848429). This study highlighted the outcomes of surgical treatment of post-infarction mechanical complications in patients operated between 2000 and 2019. Several scientific publications have resulted from this registry, which involved 27 international centers and recruited about 800 patients. However, retrospective studies are inherently limited by factors such as selection bias and a high number of missing data, affecting data interpretation and consistency of results. Moreover, most registries report only data about surgical patients or, in rare situations, about patients treated percutaneously. To overcome these limitations, a prospective study has been designed to collect more precise and focused data and achieve results that better reflect the current clinical practice, including all the patients diagnosed with post-infarction mechanical complications, independently from the treatment assigned.
"CAUTION Study - 2" is, therefore, a prospective, multicenter cohort study with the primary aim of analyzing the outcomes of surgical, percutaneous and conservative treatment of post-infarction mechanical complications in the contemporary era.
Data on patients undergoing surgical, percutaneous or conservative treatment for post-infarction mechanical complications will be prospectively collected from participating Departments of Cardiac Surgery and Cardiology from January 1st, 2025, to December 31st, 2027. According to the "CAUTION Study 1", each center treats an average of 5-10 patients per year for mechanical complications of acute myocardial infarction. Therefore, considering that at least 50 centers will participate in this study, the goal is to recruit approximately 800 patients, making this the largest prospective study on these conditions. Clinically relevant patient data will be anonymized and entered by individual centers into a dedicated data collection platform (e.g., RedCap). The accuracy of data entry will be verified by the study's promoting center, which will also handle the statistical analysis and data processing.
For every participating center, it is expected that approximately 10-15 patients will be enrolled. For each patient, demographic and clinical data such as age, gender, diagnosis, key laboratory tests, diagnostic procedures performed during hospitalization, associated diseases, description of the surgical intervention or percutaneous procedure, post-operative complications, and in-hospital outcomes will be recorded. Analysis of quality of life, the need for new hospitalizations or re-interventions, and long-term survival of recruited patients will be conducted during the annual follow-up visit, which all patients usually undergo, or through access to the regional or national electronic health record.
Patient enrollment will take place after they have reviewed the information sheet "Informed Consent to Participate in the Study: CAUTION Study 2" and have provided their consent.
- Being tested
- Surgical treatment, Percutaneous treatment
- Medical subject headings
- Heart Septal Defects, Ventricular, Heart Rupture, Aneurysm, False
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Surgical treatmentProcedure or surgery
Surgical repair of post-infarction mechanical complications (e.g. sutureless or sutured repair for LVFWR, David or Daggett technique for VSR, mitral valve repair or replacement for PMR)
Percutaneous treatmentProcedure or surgery
Percutaneous approach for the management of post-infarction mechanical complications (e.g. percutaneous closure with device for VSR, Mitraclip for PMR, PIFIT for LVFWR)
| Study group | Role | What they receive |
|---|---|---|
| Patients with post-infarction mechanical complications | All the patients diagnosed with post-infarction mechanical complications, independently from the treatment assigned (surgical, percutaneous or conservative) Receives: Procedure: Surgical treatment; Procedure: Percutaneous treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
In-hospital mortality
Mortality during the hospitalization for the management of post-infarction mechanical complication
Measured: from enrollment to the end of hospitalization (up to 30 days)
Secondary outcomes (1)
Long-term survival
Survival at 5 years from the diagnosis of post-infarction mechanical complication
Measured: from enrollment to the end of follow-up (5 years from diagnosis)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2024
- Study start1 Jan 2025
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Ventricular Septal DefectStudies of the same condition, open and under way.
- More trials run by Maastricht University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 800 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Maastricht University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06676345
- Sponsor's protocol ID
- IT-VA:56/2024
- Acronym
- CAUTION 2
- Status last verified
- May 2025
- First submitted
- 1 Nov 2024
- Last updated
- 11 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ronco D, Matteucci M, Kowalewski M, De Bonis M, Formica F, Jiritano F, Fina D, Folliguet T, Bonaros N, Russo CF, Sponga S, Vendramin I, De Vincentiis C, Ranucci M, Suwalski P, Falcetta G, Fischlein T, Troise G, Villa E, Dato GA, Carrozzini M, Serraino GF, Shah SH, Scrofani R, Fiore A, Kalisnik JM, D'Alessandro S, Lodo V, Kowalowka AR, Deja MA, Almobayedh S, Massimi G, Thielmann M, Meyns B, Khouqeer FA, Al-Attar N, Pozzi M, Obadia JF, Boeken U, Kalampokas N, Fino C, Simon C, Naito S, Beghi C, Lorusso R. Surgical Treatment of Postinfarction Ventricular Septal Rupture. JAMA Netw Open. 2021 Oct 1;4(10):e2128309. doi: 10.1001/jamanetworkopen.2021.28309.
PubMed 34668946Matteucci M, Ronco D, Kowalewski M, Massimi G, De Bonis M, Formica F, Jiritano F, Folliguet T, Bonaros N, Sponga S, Suwalski P, De Martino A, Fischlein T, Troise G, Dato GA, Serraino FG, Shah SH, Scrofani R, Kalisnik JM, Colli A, Russo CF, Ranucci M, Pettinari M, Kowalowka A, Thielmann M, Meyns B, Khouqeer F, Obadia JF, Boeken U, Simon C, Naito S, Musazzi A, Lorusso R. Long-term survival after surgical treatment for post-infarction mechanical complications: results from the Caution study. Eur Heart J Qual Care Clin Outcomes. 2024 Dec 19;10(8):737-749. doi: 10.1093/ehjqcco/qcae010.
PubMed 38327179Matteucci M, Kowalewski M, De Bonis M, Formica F, Jiritano F, Fina D, Meani P, Folliguet T, Bonaros N, Sponga S, Suwalski P, De Martino A, Fischlein T, Troise G, Dato GA, Serraino GF, Shah SH, Scrofani R, Antona C, Fiore A, Kalisnik JM, D'Alessandro S, Villa E, Lodo V, Colli A, Aldobayyan I, Massimi G, Trumello C, Beghi C, Lorusso R. Surgical Treatment of Post-Infarction Left Ventricular Free-Wall Rupture: A Multicenter Study. Ann Thorac Surg. 2021 Oct;112(4):1186-1192. doi: 10.1016/j.athoracsur.2020.11.019. Epub 2020 Dec 9.
PubMed 33307071
Study at a glance
From the registry record, last updated by the sponsor on 11 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mechanical Complications of Acute Myocardial Infarction: a Multicenter Prospective Observational Study
- ClinicalTrials.gov ID
- NCT06676345
- Acronym / sponsor ID
- CAUTION 2 / IT-VA:56/2024
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 800 participants (estimated)
- Lead sponsor
- Maastricht University Medical CenterUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2032 (estimated)
- First posted
- 6 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In 2019, the international study titled "CAUTION Study - 1" (MeChanical complicAtions of acUte myocardial infarcTion: an InternatiOnal multiceNter cohort study), a retrospective multicenter study, was launched and registered on ClinicalTrials.gov (Identifier: NCT03848429). This study highlighted the outcomes of surgical treatment of post-infarction mechanical complications in patients operated between 2000 and 2019. Several scientific publications have resulted from this registry, which involved 27 international centers and recruited about 800 patients. However, retrospective studies are inherently limited by factors such as selection bias and a high number of missing data, affecting data interpretation and consistency of results. Moreover, most registries report only data about surgical patients or, in rare situations, about patients treated percutaneously. To overcome these limitations, a prospective study has been designed to collect more precise and focused data and achieve results that better reflect the current clinical practice, including all the patients diagnosed with post-infarction mechanical complications, independently from the treatment assigned.
"CAUTION Study - 2" is, therefore, a prospective, multicenter cohort study with the primary aim of analyzing the outcomes of surgical, percutaneous and conservative treatment of post-infarction mechanical complications in the contemporary era.
Detailed description
In Western countries, cardiovascular diseases are the leading cause of death among people over 65 years old. Acute myocardial infarction represents the most frequent cardiovascular event among the heart diseases. In recent years, with the spread of percutaneous coronary reperfusion techniques, there has been a reduction in the incidence of mechanical complications of acute myocardial infarction. However, mortality in patients who develop one of these complications remains high, with mechanical complications representing a relevant cause of death in patients with acute coronary syndrome after cardiogenic shock and arrhythmia.
The acute mechanical complications of myocardial infarction include ventricular free-wall rupture (VFWR), ventricular pseudo-aneurysm, acute mitral regurgitation due to papillary muscle rupture (PMR), and ventricular septal rupture (VSR). Numerous surgical techniques and management protocols have been proposed to address these complications, but the most effective ones and those associated with better outcomes remain unclear. Recently, percutaneous treatment techniques have also been proposed in this setting (particularly for VSD and PMR), especially for high-risk surgical patients or those considered inoperable, though the safety and efficacy of these approaches remain uncertain.
In 2019, the international study titled "CAUTION Study - 1" (MeChanical complicAtions of acUte myocardial infarcTion: an InternatiOnal multiceNter cohort study), a retrospective multicenter study, was launched and registered on ClinicalTrials.gov (Identifier: NCT03848429). This study highlighted the outcomes of surgical treatment of post-infarction mechanical complications in patients operated between 2000 and 2019. Several scientific publications have resulted from this registry, which involved 27 international centers and recruited about 800 patients. However, retrospective studies are inherently limited by factors such as selection bias and a high number of missing data, affecting data interpretation and consistency of results. Moreover, most registries report only data about surgical patients or, in rare situations, about patients treated percutaneously. To overcome these limitations, a prospective study has been designed to collect more precise and focused data and achieve results that better reflect the current clinical practice, including all the patients diagnosed with post-infarction mechanical complications, independently from the treatment assigned.
"CAUTION Study - 2" is, therefore, a prospective, multicenter cohort study with the primary aim of analyzing the outcomes of surgical, percutaneous and conservative treatment of post-infarction mechanical complications in the contemporary era.
Data on patients undergoing surgical, percutaneous or conservative treatment for post-infarction mechanical complications will be prospectively collected from participating Departments of Cardiac Surgery and Cardiology from January 1st, 2025, to December 31st, 2027. According to the "CAUTION Study 1", each center treats an average of 5-10 patients per year for mechanical complications of acute myocardial infarction. Therefore, considering that at least 50 centers will participate in this study, the goal is to recruit approximately 800 patients, making this the largest prospective study on these conditions. Clinically relevant patient data will be anonymized and entered by individual centers into a dedicated data collection platform (e.g., RedCap). The accuracy of data entry will be verified by the study's promoting center, which will also handle the statistical analysis and data processing.
For every participating center, it is expected that approximately 10-15 patients will be enrolled. For each patient, demographic and clinical data such as age, gender, diagnosis, key laboratory tests, diagnostic procedures performed during hospitalization, associated diseases, description of the surgical intervention or percutaneous procedure, post-operative complications, and in-hospital outcomes will be recorded. Analysis of quality of life, the need for new hospitalizations or re-interventions, and long-term survival of recruited patients will be conducted during the annual follow-up visit, which all patients usually undergo, or through access to the regional or national electronic health record.
Patient enrollment will take place after they have reviewed the information sheet "Informed Consent to Participate in the Study: CAUTION Study 2" and have provided their consent.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with post-infarction mechanical complications | – | Procedure: Surgical treatment, Procedure: Percutaneous treatmentAll the patients diagnosed with post-infarction mechanical complications, independently from the treatment assigned (surgical, percutaneous or conservative) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients diagnosed with post-infarction mechanical complications
Key inclusion criteria (1 listed)
- all the patients diagnosed with post-infarction mechanical complications, independently from the treatment assigned
Key exclusion criteria (1 listed)
- patients with cardiac rupture not acute myocardial infarction related
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surgical treatmentSurgical repair of post-infarction mechanical complications (e.g. sutureless or sutured repair for LVFWR, David or Daggett technique for VSR, mitral valve repair or replacement for PMR) | Procedure or surgery | Patients with post-infarction mechanical complications |
| Percutaneous treatmentPercutaneous approach for the management of post-infarction mechanical complications (e.g. percutaneous closure with device for VSR, Mitraclip for PMR, PIFIT for LVFWR) | Procedure or surgery | Patients with post-infarction mechanical complications |
Primary outcome
In-hospital mortality
Time frame: from enrollment to the end of hospitalization (up to 30 days)
Mortality during the hospitalization for the management of post-infarction mechanical complication
1 secondary outcome
Long-term survival
Time frame: from enrollment to the end of follow-up (5 years from diagnosis)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 May 2025.
- Background: PubMed 34668946Ronco D, Matteucci M, Kowalewski M, De Bonis M, Formica F, Jiritano F, Fina D, Folliguet T, Bonaros N, Russo CF, Sponga S, Vendramin I, De Vincentiis C, Ranucci M, Suwalski P, Falcetta G, Fischlein T, Troise G, Villa E, Dato GA, Carrozzini M, Serraino GF, Shah SH, Scrofani R, Fiore A, Kalisnik JM, D'Alessandro S, Lodo V, Kowalowka AR, Deja MA, Almobayedh S, Massimi G, Thielmann M, Meyns B, Khouqeer FA, Al-Attar N, Pozzi M, Obadia JF, Boeken U, Kalampokas N, Fino C, Simon C, Naito S, Beghi C, Lorusso R. Surgical Treatment of Postinfarction Ventricular Septal Rupture. JAMA Netw Open. 2021 Oct 1;4(10):e2128309. doi: 10.1001/jamanetworkopen.2021.28309.
- Background: PubMed 38327179Matteucci M, Ronco D, Kowalewski M, Massimi G, De Bonis M, Formica F, Jiritano F, Folliguet T, Bonaros N, Sponga S, Suwalski P, De Martino A, Fischlein T, Troise G, Dato GA, Serraino FG, Shah SH, Scrofani R, Kalisnik JM, Colli A, Russo CF, Ranucci M, Pettinari M, Kowalowka A, Thielmann M, Meyns B, Khouqeer F, Obadia JF, Boeken U, Simon C, Naito S, Musazzi A, Lorusso R. Long-term survival after surgical treatment for post-infarction mechanical complications: results from the Caution study. Eur Heart J Qual Care Clin Outcomes. 2024 Dec 19;10(8):737-749. doi: 10.1093/ehjqcco/qcae010.
- Background: PubMed 33307071Matteucci M, Kowalewski M, De Bonis M, Formica F, Jiritano F, Fina D, Meani P, Folliguet T, Bonaros N, Sponga S, Suwalski P, De Martino A, Fischlein T, Troise G, Dato GA, Serraino GF, Shah SH, Scrofani R, Antona C, Fiore A, Kalisnik JM, D'Alessandro S, Villa E, Lodo V, Colli A, Aldobayyan I, Massimi G, Trumello C, Beghi C, Lorusso R. Surgical Treatment of Post-Infarction Left Ventricular Free-Wall Rupture: A Multicenter Study. Ann Thorac Surg. 2021 Oct;112(4):1186-1192. doi: 10.1016/j.athoracsur.2020.11.019. Epub 2020 Dec 9.
- Individual participant dataSharing planned: No
Related trials for Ventricular Septal Defect
RecruitingPhase 1
Beta-blocker Administration for Cardiomyocyte Division
Tetralogy of Fallot, Double Outlet Right Ventricle
Recruiting
Investigation of Tetralogy of Fallot in Neonates
Tetralogy of Fallot (TOF), Pulmonary Stenosis
Not yet recruiting
Dapagliflozin and Right Heart Recovery After ASD Device Closure
ASD2(Secundum Atrial Septal Defect)
RecruitingObservational study
An International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects
Perimembranous Ventricular Septal Defect
RecruitingObservational study
Abbott Structural Heart Device Registry
Heart Diseases, ASD - Atrial Septal Defect
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ventricular Septal Defect and Papillary Muscle Rupture, run by Maastricht University Medical Center at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Matteo Matteucci, MD, PhD (+39.3493556001, matteomatteucci87@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
In-hospital mortality (time frame: from enrollment to the end of hospitalization (up to 30 days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06676345, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2025.